107 STAT. 200 PUBLIC LAW 103-43—JUNE 10, 1993 42 USC 300CC-20. 42 USC 300CC-31. 42 USC 300CC-51. (ii) by striking "syndrome" and inserting "syndrome, including treatment and prevention of HIV infection and related conditions among women"; and (B) in subsection (e), by striking "1991." and inserting the following: "1991, and such sums as may be necessary for each of the fiscal years 1994 through 1996."; (5) in section 2320(b)(1)(A), by striking "syndrome" and inserting "syndrome and the natural history of such infection"; (6) in section 2320(e)(1), by striking "there are authorized" and all that follows and inserting "there are authorized to be appropriated such sums as may be necessary for each fiscal year. "; (7) in section 2341(d), by striking "there are authorized" and all that follows and inserting "there are authorized to be appropriated such sums as may be necessary for each fiscal year.; and (8) in section 2361, by striking "For purposes" and all that follows and inserting the following: "For purposes of this title: "(1) The term 'infection', with respect to the etiologic agent for acquired immune deficiency synth-ome, includes opportunistic cancers and infectious diseases and any other conditions arisingfi*ominfection with such etiologic agent. "(2) The term 'treatment', with respect to the etiologic agent for acquired immune deficiency sjnidrome, includes primary and secondary prophylaxis.". TITLE XIX—STUDIES 42 USC 282 note. 42 USC 300cc note. SEC. 1901. LIFE-THREATENING ILLNESSES. (a) THIRD-PARTY PAYMENTS REGARDING CERTAIN CLINICAL TRIALS AND CERTAIN LIFE-THREATENING ILLNESSES.— The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct a study for the purpose of— (1) determining the policies of third-party payors regarding the payment of the costs of appropriate health services that are provided incident to the participation of individuals as subjects in clinical trials conducted in the development of drugs with respect to acquired immune deficiency syndrome, cancer, and other life-threatening illnesses; and (2) developing recommendations regarding such policies. (b) VACCINES FOR HUMAN IMMUNODEFICIENCY VIRUS. — (1) IN GENERAL,—The Secretary of Health and Human Services, acting through the National Institutes of Health, shall develop a plan for the appropriate inclusion of HIV-infected women, including pregnant women, HIV-infected infants, and HIV-infected children in studies conducted by or through the National Institutes of Health concerning the safety and efficacy of HIV vaccines for the treatment and prevention of HIV infection. Such plan shall ensure the full participation of other Federal agencies currently conducting HIV vaccine studies and require that such studies conform mlly to the reqxiirements of part 46 of title 45, Code of Federal Regulations. (2) REPORT. —Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human
�
